Yesterday, Aug. 27, 2015, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $287.50 to $3,256,000.00.

Highlighted Stocks Traded by Insiders:

Valeant Pharmaceuticals International (VRX) - FREE Research Report

Farmer Ronald Harold, who is Director at Valeant Pharmaceuticals International, bought 500 shares at $220.00 on Aug. 27, 2015. Following this transaction, the Director owned 2,000 shares meaning that the stake was boosted by 33.33% with the 500-share transaction.

The shares most recently traded at $233.16, up $13.16, or 5.64% since the insider transaction. Historical insider transactions for Valeant Pharmaceuticals International go as follows:

  • 4-Week # shares bought: 7,875
  • 4-Week # shares sold: 23,000
  • 12-Week # shares bought: 21,275
  • 12-Week # shares sold: 23,000
  • 24-Week # shares bought: 28,775
  • 24-Week # shares sold: 23,000

The average volume for Valeant Pharmaceuticals International has been 1.8 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $77.9 billion and is part of the health care sector and drugs industry. Shares are up 64.14% year-to-date as of the close of trading on Thursday.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company has a P/E ratio of 93.5. Currently, there are 8 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRX - FREE

TheStreet Quant Ratings rates Valeant Pharmaceuticals International as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, expanding profit margins, solid stock price performance and notable return on equity. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Valeant Pharmaceuticals International Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

West (WSTC) - FREE Research Report

Adrean Lee, who is Director at West, bought 4,000 shares at $22.86 on Aug. 27, 2015. Following this transaction, the Director owned 11,449 shares meaning that the stake was boosted by 53.7% with the 4,000-share transaction.

The shares most recently traded at $23.41, up $0.55, or 2.35% since the insider transaction. Historical insider transactions for West go as follows:

  • 4-Week # shares bought: 7,400
  • 4-Week # shares sold: 9,959
  • 12-Week # shares bought: 7,400
  • 12-Week # shares sold: 9,959
  • 24-Week # shares bought: 7,400
  • 24-Week # shares sold: 9,959

The average volume for West has been 473,600 shares per day over the past 30 days. West has a market cap of $1.9 billion and is part of the technology sector and telecommunications industry. Shares are down 29.76% year-to-date as of the close of trading on Thursday.

West Corporation, together with its subsidiaries, provides technology-enabled communication services in the United States, Canada, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and South America. It operates in two segments, Unified Communications and Communication Services. The stock currently has a dividend yield of 3.89%. The company has a P/E ratio of 13.6. Currently, there are 5 analysts who rate West a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WSTC - FREE

TheStreet Quant Ratings rates West as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full West Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cepheid (CPHD) - FREE Research Report

Smith Joseph H, who is EVP, Bus Dev and GC at Cepheid, bought 10,000 shares at $47.54 on Aug. 27, 2015. Following this transaction, the EVP, Bus Dev and GC owned 25,897 shares meaning that the stake was boosted by 62.9% with the 10,000-share transaction.

The shares most recently traded at $49.97, up $2.43, or 4.87% since the insider transaction. Historical insider transactions for Cepheid go as follows:

  • 4-Week # shares sold: 7,048
  • 12-Week # shares sold: 7,223
  • 24-Week # shares sold: 8,250

The average volume for Cepheid has been 715,500 shares per day over the past 30 days. Cepheid has a market cap of $3.5 billion and is part of the technology sector and electronics industry. Shares are down 8.88% year-to-date as of the close of trading on Thursday.

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. Currently, there are 12 analysts who rate Cepheid a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CPHD - FREE

TheStreet Quant Ratings rates Cepheid as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Cepheid Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.